+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032- Product Image
Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888133
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Glioblastoma Multiforme Treatment Market is projected to reach USD 3.97 Billion in 2026. It is expected to continue growing at a CAGR of 8.35%, reaching USD 6.41 Billion by 2032.

Glioblastoma multiforme is an aggressive primary brain tumor characterized by rapid progression, diffuse infiltration, molecular heterogeneity, and frequent recurrence. Treatment generally combines maximal safe surgical resection, radiotherapy, and systemic therapy, followed by surveillance and management of neurological, cognitive, and treatment-related effects. Clinical decision-making increasingly incorporates tumor molecular profiling, performance status, age, comorbidities, steroid exposure, and patient preferences. Because recurrence is common and therapeutic responses vary, care requires coordinated neurosurgical, neuro-oncology, radiation, pathology, imaging, rehabilitation, and palliative services.

Precision Diagnostics and Integrated Care Are Reshaping Glioblastoma Management

The treatment landscape is shifting from uniform protocols toward biologically informed and patient-adapted care. Molecular classification, including assessment of markers such as IDH status, MGMT promoter methylation, TERT alterations, EGFR changes, and chromosomal abnormalities, helps refine diagnosis, prognosis, and treatment planning. Advanced imaging, fluorescence-guided surgery, intraoperative mapping, hypofractionated radiotherapy for selected patients, tumor-treating fields, reirradiation, and clinical trials are expanding the range of options considered across disease stages. Supportive care is also becoming more integrated, with greater attention to seizure control, edema management, cognition, rehabilitation, psychosocial needs, and caregiver support.

Artificial Intelligence Is Accelerating Imaging, Pathology, and Trial Decision Support

Artificial intelligence is being evaluated across glioblastoma care, particularly for radiographic segmentation, differentiation of treatment effect from tumor progression, digital pathology, molecular prediction, surgical planning, and longitudinal outcome analysis. These tools may reduce interpretation variability and help clinicians combine imaging, pathology, genomic, and clinical data. However, deployment requires representative datasets, external validation, transparent performance reporting, cybersecurity safeguards, interoperability, and clinician oversight. Bias from single-center data, inconsistent imaging protocols, limited rare-subgroup representation, and uncertainty around regulatory accountability remains important. AI is therefore best positioned as decision support rather than a substitute for multidisciplinary clinical judgment.

Regional Differences Reflect Research Capacity, Access, and Care Coordination

North America generally combines advanced neuro-oncology infrastructure, molecular diagnostics, clinical-trial activity, and specialized academic centers, although access and insurance coverage can vary. Europe benefits from established referral networks and research collaboration, while differences in national reimbursement, trial availability, and guideline implementation influence treatment pathways. Asia-Pacific includes sophisticated centers alongside substantial variation in diagnostic access, specialist availability, and affordability across economies. Latin America faces uneven access to advanced imaging, molecular testing, radiotherapy, and comprehensive supportive care. The Middle East shows expanding specialist capacity in some countries but continued dependence on concentrated referral centers. Africa experiences pronounced disparities in neurosurgical services, pathology, radiotherapy, medicines, and follow-up, making infrastructure development and regional partnerships central priorities.

International Groups Highlight Shared Standards but Unequal Implementation

ASEAN countries are working across highly varied health systems, with collaboration and referral models helping address differences in specialist and diagnostic capacity. BRICS members span major academic research centers and settings where access to molecular testing, radiotherapy, and innovative therapies remains uneven. The European Union supports cross-border research, common regulatory frameworks, and clinical collaboration, while national differences continue in reimbursement and service delivery. G7 countries possess substantial research and specialist capacity but still face challenges involving aging populations, affordability, trial recruitment, and equitable access. GCC states are strengthening tertiary oncology infrastructure and specialist services, often through concentrated national programs. NATO members encompass diverse health systems, and opportunities remain for shared research, preparedness, data standards, and cross-border expertise.

Country-Level Priorities Vary From Innovation Capacity to Basic Access

Australia supports specialist neuro-oncology networks and research collaboration across geographically dispersed populations. Brazil and Mexico continue to address regional inequities in neurosurgery, radiotherapy, pathology, and access to clinical trials. Canada and the United States have strong academic treatment and research capabilities, alongside geographic, financial, and insurance-related access challenges. China and India combine expanding research capacity with substantial variation between major urban centers and underserved regions. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have established specialist services, but face differing pressures related to aging, workforce capacity, reimbursement, and trial access. Russia’s capabilities are concentrated unevenly, with continuity of specialized diagnostics, medicines, and research participation influenced by geography and health-system constraints.

Leaders Should Prioritize Molecular Access, Coordinated Care, and Evidence Generation

Industry and health-system leaders should expand timely access to standardized molecular diagnostics, validated imaging, and multidisciplinary review, especially outside major academic centers. Treatment pathways should be designed around patient fitness, tumor biology, recurrence status, functional goals, and caregiver needs rather than a single uniform sequence. Partnerships with hospitals, laboratories, regulators, patient organizations, and research networks can improve trial referral, real-world evidence, and representation of underserved populations. AI programs should begin with clearly defined clinical use cases, prospective validation, monitoring for bias, and human accountability. Investment in rehabilitation, palliative care, remote follow-up, data interoperability, and clinician education can improve continuity and make innovation more clinically useful.

Methodology: Evidence-Based Synthesis of Clinical, Regulatory, and Health-System Factors

This executive summary uses a structured qualitative review framework focused on glioblastoma diagnosis, treatment, recurrence management, supportive care, technology adoption, and access conditions. Evidence should be triangulated across peer-reviewed clinical studies, authoritative clinical guidelines, regulatory documents, public health sources, trial registries, and validated health-system reports. Findings are organized by treatment evolution, artificial intelligence applications, geography, and international groupings, with attention to differences in infrastructure, reimbursement, workforce, research participation, and patient needs. Claims should be checked for source quality, publication date, methodological limitations, and applicability across populations; no unsupported numerical estimates or commercial ranking claims are used.

The Next Phase Depends on Precision, Coordination, and Equitable Delivery

Glioblastoma treatment is advancing through more precise classification, improved surgical and imaging support, broader clinical-trial activity, and increasingly coordinated supportive care. Yet aggressive disease biology, recurrence, treatment toxicity, and uneven access continue to limit outcomes. The most durable progress will require linking molecular diagnostics and innovative therapies with rigorous evidence generation, responsible AI, multidisciplinary delivery, rehabilitation, palliative services, and patient-centered communication. Regional collaboration and targeted infrastructure investment are essential to ensure that advances reach patients beyond the best-resourced specialist centers.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Glioblastoma Multiforme Treatment Market, by Treatment Type
7.1. Introduction
7.2. Drug Therapy
7.2.1. Chemotherapy
7.2.1.1. Carmustine
7.2.1.2. Combination Chemotherapy
7.2.1.3. Temozolomide
7.2.2. Gene Therapy
7.2.2.1. Gene Editing
7.2.2.2. Oncolytic Virus Therapy
7.2.3. Immunotherapy
7.2.3.1. Checkpoint Inhibitors
7.2.3.2. Vaccines
7.2.4. Targeted Therapy
7.2.4.1. Bevacizumab
7.2.4.2. EGFR Inhibitors
7.3. Radiotherapy
7.3.1. Brachytherapy
7.3.2. External Beam Radiotherapy
7.3.3. Radiosurgery
7.4. Supportive Care
7.4.1. Antiepileptic Drugs
7.4.2. Corticosteroids
7.5. Surgical
7.5.1. Biopsy Procedures
7.5.2. Craniotomy
8. Glioblastoma Multiforme Treatment Market, by Drug Class
8.1. Introduction
8.2. Alkylating Agents
8.2.1. Carmustine
8.2.2. Temozolomide
8.3. Checkpoint Inhibitors
8.3.1. Nivolumab
8.3.2. Pembrolizumab
8.4. Monoclonal Antibodies
8.5. Oncolytic Virus Therapies
8.6. Vaccine Therapies
8.6.1. Dendritic Cell Vaccines
8.6.2. Peptide Vaccines
9. Glioblastoma Multiforme Treatment Market, by Line Of Therapy
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line
10. Glioblastoma Multiforme Treatment Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.3. Hospitals
10.4. Research Institutes
10.5. Specialty Clinics
11. Glioblastoma Multiforme Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Online
11.3. Offline
12. Glioblastoma Multiforme Treatment Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Glioblastoma Multiforme Treatment Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Glioblastoma Multiforme Treatment Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Amgen Inc.
16.3. Amneal Pharmaceuticals Inc.
16.4. AstraZeneca PLC
16.5. Bayer AG
16.6. Biohaven Ltd
16.7. Bluebird Bio Inc.
16.8. Bristol-Myers Squibb Company
16.9. Celldex Therapeutics Inc.
16.10. Chimerix Inc.
16.11. CNS Pharmaceuticals Inc.
16.12. Daiichi Sankyo Company Limited
16.13. Eisai Co. Ltd
16.14. Eli Lilly and Company
16.15. Enterome SA
16.16. F. Hoffmann-La Roche Ltd
16.17. Karyopharm Therapeutics Inc.
16.18. Kazia Therapeutics Limited
16.19. Lantern Pharma Inc.
16.20. Medicenna Therapeutics Corp
16.21. Merck & Co. Inc.
16.22. Northwest Biotherapeutics Inc.
16.23. Novartis AG
16.24. Novocure Ltd
16.25. Orbus Therapeutics Inc.
16.26. Pfizer Inc.
16.27. Sun Pharmaceutical Industries Ltd
16.28. Teva Pharmaceutical Industries Ltd
16.29. TuHURA Biosciences Inc.
16.30. Vigeo Therapeutics Inc.
17. Key Experts
List of Figures
FIGURE 1. Global Glioblastoma Multiforme Treatment Market, Years Considered for the Study
FIGURE 2. Global Glioblastoma Multiforme Treatment Market, Research Design
FIGURE 3. Global Glioblastoma Multiforme Treatment Market, Research Framework
FIGURE 4. Global Glioblastoma Multiforme Treatment Market, Data Triangulation
FIGURE 5. Global Glioblastoma Multiforme Treatment Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 7. Global Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 9. Global Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2025 vs 2032 (%)
FIGURE 11. Global Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Glioblastoma Multiforme Treatment Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Glioblastoma Multiforme Treatment Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Glioblastoma Multiforme Treatment Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Glioblastoma Multiforme Treatment Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Glioblastoma Multiforme Treatment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Glioblastoma Multiforme Treatment Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Glioblastoma Multiforme Treatment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Glioblastoma Multiforme Treatment Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Glioblastoma Multiforme Treatment Market Segmentation & Coverage
TABLE 2. Global Glioblastoma Multiforme Treatment Market Size, 2017-2032 (USD Million)
TABLE 3. Global Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 4. Global Drug Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Drug Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Drug Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Chemotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Chemotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Chemotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Carmustine Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Carmustine Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Carmustine Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Combination Chemotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Combination Chemotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Combination Chemotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Temozolomide Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Temozolomide Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Temozolomide Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Gene Editing Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Gene Editing Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Gene Editing Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Oncolytic Virus Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Oncolytic Virus Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Oncolytic Virus Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Immunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Immunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Checkpoint Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Targeted Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Targeted Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Targeted Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Bevacizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Bevacizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Bevacizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global EGFR Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global EGFR Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global EGFR Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Radiotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Radiotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Radiotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Brachytherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Brachytherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Brachytherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global External Beam Radiotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global External Beam Radiotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global External Beam Radiotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Radiosurgery Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Radiosurgery Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Radiosurgery Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Supportive Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Supportive Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Supportive Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Antiepileptic Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Antiepileptic Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Antiepileptic Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Surgical Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Surgical Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Surgical Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Biopsy Procedures Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Biopsy Procedures Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Biopsy Procedures Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Craniotomy Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Craniotomy Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Craniotomy Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 77. Global Alkylating Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Alkylating Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Alkylating Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Carmustine Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Carmustine Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Carmustine Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Temozolomide Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Temozolomide Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Temozolomide Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Checkpoint Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Nivolumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Nivolumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Nivolumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Pembrolizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Pembrolizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Pembrolizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Oncolytic Virus Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Oncolytic Virus Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Oncolytic Virus Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Vaccine Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Vaccine Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Vaccine Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Dendritic Cell Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Dendritic Cell Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Dendritic Cell Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Peptide Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Peptide Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Peptide Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 111. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Third Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Third Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Third Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 127. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 128. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 130. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 133. Global Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Glioblastoma Multiforme Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 143. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 144. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 145. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 146. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 147. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 148. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 149. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 150. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 151. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 152. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 153. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 154. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 155. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 158. North America Glioblastoma Multiforme Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. North America Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 160. North America Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 161. North America Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 162. North America Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 163. North America Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 164. North America Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 165. North America Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 166. North America Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 167. North America Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 168. North America Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 169. North America Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 170. North America Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 171. North America Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 172. North America Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 173. North America Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. North America Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. Latin America Glioblastoma Multiforme Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 176. Latin America Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 177. Latin America Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 178. Latin America Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 179. Latin America Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 180. Latin America Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 181. Latin America Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 182. Latin America Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 183. Latin America Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 184. Latin America Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 185. Latin America Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 186. Latin America Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 187. Latin America Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 188. Latin America Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 189. Latin America Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 190. Latin America Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. Latin America Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. Europe Glioblastoma Multiforme Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 193. Europe Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 194. Europe Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 195. Europe Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 196. Europe Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 197. Europe Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 198. Europe Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 199. Europe Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 200. Europe Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 201. Europe Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 202. Europe Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 203. Europe Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 204. Europe Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 205. Europe Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 206. Europe Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 207. Europe Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Europe Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. Middle East Glioblastoma Multiforme Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 210. Middle East Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 211. Middle East Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 212. Middle East Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 213. Middle East Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 214. Middle East Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 215. Middle East Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 216. Middle East Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 217. Middle East Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 218. Middle East Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 219. Middle East Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 220. Middle East Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 221. Middle East Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 222. Middle East Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 223. Middle East Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 224. Middle East Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. Middle East Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Africa Glioblastoma Multiforme Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 227. Africa Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 228. Africa Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 229. Africa Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 230. Africa Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 231. Africa Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 232. Africa Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 233. Africa Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 234. Africa Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 235. Africa Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 236. Africa Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 237. Africa Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 238. Africa Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 239. Africa Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 240. Africa Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 241. Africa Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 242. Africa Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 243. Global Glioblastoma Multiforme Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 244. ASEAN Glioblastoma Multiforme Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 245. ASEAN Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 246. ASEAN Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 247. ASEAN Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 248. ASEAN Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 249. ASEAN Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 250. ASEAN Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 251. ASEAN Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 252. ASEAN Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 253. ASEAN Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 254. ASEAN Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 255. ASEAN Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 256. ASEAN Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 257. ASEAN Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 258. ASEAN Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 259. ASEAN Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. ASEAN Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 261. GCC Glioblastoma Multiforme Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 262. GCC Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 263. GCC Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 264. GCC Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 265. GCC Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 266. GCC Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 267. GCC Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 268. GCC Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 269. GCC Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 270. GCC Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 271. GCC Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 272. GCC Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 273. GCC Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 274. GCC Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 275. GCC Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 276. GCC Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 277. GCC Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 278. European Union Glioblastoma Multiforme Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 279. European Union Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 280. European Union Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 281. European Union Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 282. European Union Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 283. European Union Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 284. European Union Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 285. European Union Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 286. European Union Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 287. European Union Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 288. European Union Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 289. European Union Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 290. European Union Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 291. European Union Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 292. European Union Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 293. European Union Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 294. European Union Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. BRICS Glioblastoma Multiforme Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 296. BRICS Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 297. BRICS Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 298. BRICS Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 299. BRICS Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 300. BRICS Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 301. BRICS Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 302. BRICS Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 303. BRICS Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 304. BRICS Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 305. BRICS Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 306. BRICS Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 307. BRICS Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 308. BRICS Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 309. BRICS Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 310. BRICS Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 311. BRICS Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 312. G7 Glioblastoma Multiforme Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 313. G7 Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 314. G7 Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 315. G7 Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 316. G7 Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 317. G7 Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 318. G7 Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 319. G7 Glioblastoma Multiforme Treatment Market Size, by Radiotherapy, 2017-2032 (USD Million)
TABLE 320. G7 Glioblastoma Multiforme Treatment Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 321. G7 Glioblastoma Multiforme Treatment Market Size, by Surgical, 2017-2032 (USD Million)
TABLE 322. G7 Glioblastoma Multiforme Treatment Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 323. G7 Glioblastoma Multiforme Treatment Market Size, by Alkylating Agents, 2017-2032 (USD Million)
TABLE 324. G7 Glioblastoma Multiforme Treatment Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 325. G7 Glioblastoma Multiforme Treatment Market Size, by Vaccine Therapies, 2017-2032 (USD Million)
TABLE 326. G7 Glioblastoma Multiforme Treatment Market Size, by Line Of Therapy, 2017-2032 (USD Million)
TABLE 327. G7 Glioblastoma Multiforme Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 328. G7 Glioblastoma Multiforme Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 329. NATO Glioblastoma Multiforme Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 330. NATO Glioblastoma Multiforme Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 331. NATO Glioblastoma Multiforme Treatment Market Size, by Drug Therapy, 2017-2032 (USD Million)
TABLE 332. NATO Glioblastoma Multiforme Treatment Market Size, by Chemotherapy, 2017-2032 (USD Million)
TABLE 333. NATO Glioblastoma Multiforme Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 334. NATO Glioblastoma Multiforme Treatment Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 335. NATO Glioblastoma Multiforme Treatment Market Size, by Targeted Therapy, 2017-2032 (USD Milli

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biohaven Ltd
  • Bluebird Bio Inc.
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics Inc.
  • Chimerix Inc.
  • CNS Pharmaceuticals Inc.
  • Daiichi Sankyo Company Limited
  • Eisai Co. Ltd
  • Eli Lilly and Company
  • Enterome SA
  • F. Hoffmann-La Roche Ltd
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Lantern Pharma Inc.
  • Medicenna Therapeutics Corp
  • Merck & Co. Inc.
  • Northwest Biotherapeutics Inc.
  • Novartis AG
  • Novocure Ltd
  • Orbus Therapeutics Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • TuHURA Biosciences Inc.
  • Vigeo Therapeutics Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.97 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.41 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report by Treatment, End Use, Region, and Segment Forecasts, 2026-2033 - Product Image

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report by Treatment, End Use, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Glioblastoma Multiforme Treatment Market Report by Drug Type, Route of Administration, Type of Molecule, Distribution Channel, and Region 2026-2034 - Product Image

Glioblastoma Multiforme Treatment Market Report by Drug Type, Route of Administration, Type of Molecule, Distribution Channel, and Region 2026-2034

  • Report
  • 137 Pages
  • Global
From
Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report - Product Image

Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Glioblastoma Multiforme Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Treatment Modality, Patient Type, End User, Age Group - Product Image

Glioblastoma Multiforme Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Treatment Modality, Patient Type, End User, Age Group

  • Report
  • 160 Pages
  • Global
From
Glioblastoma Multiforme Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Glioblastoma Multiforme Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.